AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Gold and Silver Hit Record Highs as Safe-Haven Demand Surges Amid Global Uncertainty 
China to Tighten Crude Steel Output Controls and Export Regulation Through 2030 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
BOJ Minutes Reveal Growing Debate Over Interest Rate Hikes and Inflation Risks 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Japan Revises Economic Growth Forecast as Stimulus Fuels Consumption and Investment 
Russian Stocks End Lower as Energy and Mining Shares Weigh on MOEX Index 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Oil Prices Ease in Asia as Geopolitical Risks Clash With Weak Demand Outlook 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Samsung Group is currently negotiating to acquire Biogen Inc., the American biotech company headquartered in Cambridge, Massachusetts. If the talks turn out to be successful, it will be the South Korean manufacturing conglomerate's biggest transaction ever.
Samsung Group is really interested in the mega-deal proposal from Biogen Inc., and this is set to become its largest acquisition. In 2016, the company set a record for its largest transaction ever after buying Harman, an American electronics systems maker for vehicles, for $8 billion. Now, its possible acquisition of the biotech firm will top this amount by more than five times over.
According to The Korea Economic Daily, Biogen Inc. spoke to Samsung to offer some of its shares that could be worth over ₩50 trillion or about $42 billion, including the control premium. The biotech firm's market cap at the moment is moderately less than $35 billion.
An investment banking source revealed on Wednesday, Dec. 29, that Samsung Group may buy the US-based drugmaker that specializes in neurological diseases, including dementia and Alzheimer's. "Samsung is at the negotiating table with the sell-side to acquire Biogen," a senior official at a global investment bank told KED.
In case the stake acquisition turns out to be successful, Samsung will become one of the top-ranking global biotechnology companies. It will also be able to expand its pharmaceutical business and do more aside from biosimilar treatment drugs and manufacturing deals. As for Biogen, it is also expected to steadily make high operating profits once the deal is sealed.
"Samsung is nurturing bio business as a new growth engine," another insider stated. "Acquiring Biogen will create an opportunity to take a quantum leap."
If the acquisition talks failed, it was reported that Samsung would attempt to buy back the remaining stake owned by Biogen in Samsung Bioepis, their biosimilar joint venture. Meanwhile, the response to the acquisition news was good so far as Biogen's stock went up after the report was published.
Market Watch reported that Biogen's shares increased 8.9 percent in the afternoon trading on Wednesday, just after it was reported that Samsung Group is on the negotiation table with the US-based drugmaker to purchase stakes in the company that is valued at around $42 billion.
